MktsMarkets
aTyr Pharma, Inc.
NASDAQ: ATYRKey statistics
ATYR News
Stories mentioning ATYR from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 190.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | |||||||
| Operating Expenses | ||||||||
| Research & Development | 7,317 | 10,891 | 22,130 | 15,384 | 11,814 | 12,228 | 14,807 | 13,973 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 11,436 | 14,796 | 26,935 | 20,313 | 15,773 | 15,820 | 18,143 | 17,315 |
| Operating Income (Loss) | (11,436) | (14,796) | (26,745) | (20,313) | (15,773) | (15,820) | (18,143) | (17,315) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (10,791) | (13,963) | (25,744) | (19,531) | (14,880) | (14,967) | (17,259) | (16,306) |
| Earnings Per Share (Basic) | (0.11) | (0.15) | (0.26) | (0.22) | (0.17) | (0.20) | (0.23) | (0.23) |
| Earnings Per Share (Diluted) | (0.11) | (0.15) | (0.26) | (0.22) | (0.17) | (0.20) | (0.23) | (0.23) |
| Weighted Average Shares Outstanding (Basic) | 98,044 | 92,985 | 97,154 | 90,120 | 86,485 | 74,261 | 75,802 | 72,284 |
| Weighted Average Shares Outstanding (Diluted) | 98,044 | 92,985 | 97,154 | 90,120 | 86,485 | 74,261 | 75,802 | 72,284 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ATYR
aTyr Pharma, Inc. (NASDAQ: ATYR) is a stock listed on the Nasdaq Stock Market under the ticker symbol ATYR. It last traded at $0.1700 (Oct 20, 2026, 4:00 PM ET), up 0.9% on the day. That gives aTyr Pharma a market capitalisation of $17.2M.
Over the past 52 weeks ATYR has traded between $0.1700 and $1.11.
For the quarter ended Mar 31, 2026 it reported a net loss of $10.8M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | — | -$10.8M | — |
| Dec 31, 2025 | $0 | -$14.0M | — |
| Sep 30, 2025 | $190.0K | -$25.7M | -13549.5% |
| Jun 30, 2025 | $0 | -$19.5M | — |
From aTyr Pharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…